Altimmune, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Altimmune, Inc. now
Current reporting with the operating signal separated from the noise.
Altimmune, Inc: Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
The development tests whether Altimmune, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Investors are testing whether Altimmune, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Altimmune, Inc. Sued for Securities Law Violations
The story matters when it changes Altimmune, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data
The story matters when it changes Altimmune, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Altimmune, Inc. Expands Board of Directors with Appointments of Teri Lawver and Jerry Durso
The story matters when it changes Altimmune, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript
Investors are testing whether Altimmune, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Robbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
Investors are testing whether Altimmune, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest ALT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Altimmune, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →